Dallas, Texas (PRWEB) August 19, 2013
Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a heterogeneous disease, and many subtypes have been identified. The current standard of care consists of cytarabine-based chemotherapy, which can often achieve remission. However, the majority of patients relapse, and survival rates are grim. There are clear unmet needs for treatments that can prolong the overall survival of these patients, but drug manufacturers have struggled to gain regulatory approval for new therapies.
This report focuses on the remaining opportunity in AML (Acute Myeloid Leukemia - http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html) exclusive of the acute promyleocytic leukemia (APL) subtype.
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=267301 . Alternatively can get DISCOUNT @ http://www.reportsnreports.com/contacts/discount.aspx?name=267301 .
Reasons to Buy
Key Questions Answered
Explore more reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com (http://www.reportsnreports.com/) is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.
Read the full story at http://www.prweb.com/releases/acute-myeloid-leukemia/market-aml-2017-forecast/prweb11038556.htm.
Copyright©2012 Vocus, Inc.
All rights reserved